Monday, 16 Sep 2019

You are here

EULAR 2019 – Day 3 Report

The third day of EULAR 2019 started with novel biologics, the efficacy of secukinumab in axial psoriatic arthritis, neurologic events with TNF inhibitors from the DANBIO database (OP0261), and neuropathy in SLE (OP0252), but above all this was a big poster day. Here are selected highlights from day 3 EULAR in Madrid.

  • CV Risk in Gout Correlates with NETs -  A study from the Reade Amsterdam Gout cohort studied 75 gout  patients - many with chronic polyarticular (71%) and tophaceous gout (21%) – to assess if neutrophil extracellular traps (NETs) and other markers of neutrophil activation (peroxidase activity) are seen in gout patients and if NETs could be cardiovascular risk calculated for individual patients.   They convincingly showed that NETs and markers of neutrophil activation and inflammatory markers were correlated with clinical features of gout, especially in polyarticular patients.  Netosis, perioxidase activity and calprotectin levels were elevated in gout patients compared to healthy controls. ETs were also correlated with cardiovascular risk scores.  It appears this strong neutrophil activation profile adds to the cardiovascular risks experienced by gout patients. OP0300
  • MAXIMISE study: It is estimated that 10% of psoriatic arthritis (PsA) patients will have axial disease (often with HLA-B27 positivity). Secukinumab is FDA approved for both PsA and AS.  The MAXIMISE study was a 52 weeks, phase 3, RCT of secukinumab IN 498 PsA patients with axial involvement. At 12 weeks, SEC treated patients had a >60% ASAS20 using either 150mg or 300 mg every 4 weeks (after a weekly loading regimen).  Good news for another subset of PsA patients. OP0235


The author has received research/grant financial support on this subject

Add new comment

More Like This

RheumNow Podcast – The End of Arthritis (9.13.19)

Dr. Jack Cush reviews the news and journal articles from the past week on

RheumNow Podcast – Do’s and Don’ts in Spondylitis (9.5.19)

Dr. Jack Cush reviews the news and important research published in the last two weeks on

Influenza Vaccination Update

FDA's Vaccines and Related Biological Products Advisory Committee met in Silver Spring, Maryland, on March 6 and 22, 2019, to select the influenza viruses for the composition of the influenza vaccine for the 2019-2020 U.S. influenza season.

RheumNow Podcast - I Wanna New Drug (8-30-19)

Dr. Jack Cush vents on choosing new therapies in rheumatoid arthritis.

RheumNow Podcast – Upadacitinib FDA Approved for RA (8.23.19)

Dr. Jack Cush reports on the news and journal reports from the past week on, including: how your genetics may shape your microbiome; GERD as a risk factor for TMJ?; how can MDA-5+ dermatomyositis be any worse; new drug happenings;; and more.